Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
暂无分享,去创建一个
Peter G. Schultz | Feng Wang | William R. Jacobs | Catherine Vilchèze | P. Schultz | V. Nizet | M. Hensler | C. Vilchèze | W. Jacobs | A. Chatterjee | Xiaozhou Luo | Victor Nizet | Feng Wang | Arnab K. Chatterjee | Hui Guo | Baiyuan Yang | Xiaozhou Luo | Baiyuan Yang | Mary E. Hensler | Michael B. Harbut | Hui Guo
[1] W. Buchanan,et al. Auranofin. , 2020, British journal of rheumatology.
[2] U. Schaible,et al. Optimisation of Bioluminescent Reporters for Use with Mycobacteria , 2010, PloS one.
[3] A. Barrios,et al. Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I). , 2004, Bioorganic & medicinal chemistry letters.
[4] A. Klegeris,et al. The biological activity of auranofin: implications for novel treatment of diseases , 2012, Inflammopharmacology.
[5] S. Engelmann,et al. Thioredoxin Is an Essential Protein Induced by Multiple Stresses in Bacillus subtilis , 1998, Journal of bacteriology.
[6] E. Davioud‐Charvet,et al. Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target , 2007, PLoS medicine.
[7] R. Basaraba. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. , 2008, Tuberculosis.
[8] E. Rubin,et al. Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.
[9] J. Collins,et al. How antibiotics kill bacteria: from targets to networks , 2010, Nature Reviews Microbiology.
[10] B. Murray,et al. Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, The New England journal of medicine.
[11] Graham R. Stewart,et al. Tuberculosis: a problem with persistence , 2003, Nature Reviews Microbiology.
[12] A. Holmgren,et al. The thioredoxin antioxidant system. , 2014, Free radical biology & medicine.
[13] J. Betts,et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.
[14] W. B. Adams,et al. Occurrence of glutathione in bacteria , 1978, Journal of bacteriology.
[15] Leopold Flohé,et al. Multiple thioredoxin-mediated routes to detoxify hydroperoxides in Mycobacterium tuberculosis. , 2004, Archives of biochemistry and biophysics.
[16] J. Helmann,et al. Biosynthesis and functions of bacillithiol, a major low-molecular-weight thiol in Bacilli , 2010, Proceedings of the National Academy of Sciences.
[17] R. Schirmer,et al. Human Placenta Thioredoxin Reductase , 1998, The Journal of Biological Chemistry.
[18] I. Borovok,et al. Transcriptional Regulation of the Staphylococcus aureus Thioredoxin and Thioredoxin Reductase Genes in Response to Oxygen and Disulfide Stress , 2004, Journal of bacteriology.
[19] A. Holmgren,et al. Protein disulfide-isomerase is a substrate for thioredoxin reductase and has thioredoxin-like activity. , 1990, The Journal of biological chemistry.
[20] S. Miller,et al. Alternative routes for entry of HgX2 into the active site of mercuric ion reductase depend on the nature of the X ligands. , 1999, Biochemistry.
[21] James C. Sacchettini,et al. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis , 2008, Nature Reviews Microbiology.
[22] J. Gut,et al. A Reprofiled Drug, Auranofin, Is Effective against Metronidazole-Resistant Giardia lamblia , 2013, Antimicrobial Agents and Chemotherapy.
[23] Mark Borodovsky,et al. The complete genome sequence of the gastric pathogen Helicobacter pylori , 1997, Nature.
[24] R. Schirmer,et al. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[25] Dae-Myung Jue,et al. Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit , 2003, Experimental & Molecular Medicine.
[26] Eric Arnoult,et al. The challenge of new drug discovery for tuberculosis , 2011, Nature.
[27] H. Mori,et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection , 2006, Molecular systems biology.
[28] Blodgett Rc,et al. Long-term efficacy and safety of auranofin: a review of clinical experience. , 1986 .
[29] V. Nizet,et al. Anthracimycin Activity Against Contemporary Methicillin-Resistant Staphylococcus aureus , 2014, The Journal of Antibiotics.
[30] A. Holmgren,et al. The use of thiols by ribonucleotide reductase. , 2010, Free radical biology & medicine.
[31] A. Miele,et al. Inhibition of Schistosoma mansoni Thioredoxin-glutathione Reductase by Auranofin , 2009, The Journal of Biological Chemistry.
[32] J. Davies,et al. Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes , 1996, Journal of bacteriology.
[33] M. Suarez‐Almazor,et al. Auranofin versus placebo in rheumatoid arthritis. , 2000, The Cochrane database of systematic reviews.
[34] Roberta B Carey,et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.
[35] R. C. Fahey. Glutathione analogs in prokaryotes. , 2013, Biochimica et biophysica acta.
[36] M. Gramiccia,et al. A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition , 2011, Amino Acids.
[37] R. Pietrusko,et al. Long-term efficacy and safety of auranofin: a review of clinical experience. , 1986, Scandinavian journal of rheumatology. Supplement.
[38] L. Messori,et al. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections , 2014, BioMetals.
[39] P. François,et al. Importance of Bacillithiol in the Oxidative Stress Response of Staphylococcus aureus , 2013, Infection and Immunity.
[40] D. Jue,et al. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. , 2003, Experimental and Molecular Medicine.
[41] J. Blanchard,et al. Expression, purification, and characterization of Mycobacterium tuberculosis mycothione reductase. , 1999, Biochemistry.
[42] Bing Chen,et al. Specialized Transduction Designed for Precise High-Throughput Unmarked Deletions in Mycobacterium tuberculosis , 2014, mBio.
[43] Alimuddin Zumla,et al. Drug-resistant tuberculosis: time for visionary political leadership. , 2013, The Lancet. Infectious diseases.
[44] S. Cole,et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. , 2014, The Lancet. Infectious diseases.
[45] P. Reichard,et al. ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOTIDES.V. PURIFICATION AND PROPERTIES OF THIOREDOXIN REDUCTASE FROM ESCHERICHIA COLI B. , 1964, The Journal of biological chemistry.
[46] W. Buchanan,et al. Disease-modifying drugs series editor : T. PULLAR AURANOFIN , 1997 .
[47] T. Pruett. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .
[48] N. Bottini,et al. Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study. , 2008, Journal of medicinal chemistry.
[49] J. Beckwith,et al. Roles of thiol-redox pathways in bacteria. , 2001, Annual review of microbiology.
[50] J. Beckwith,et al. The Role of the Thioredoxin and Glutaredoxin Pathways in Reducing Protein Disulfide Bonds in the Escherichia coliCytoplasm* , 1997, The Journal of Biological Chemistry.
[51] Thomas R. Ioerger,et al. High-Resolution Phenotypic Profiling Defines Genes Essential for Mycobacterial Growth and Cholesterol Catabolism , 2011, PLoS pathogens.
[52] David Alland,et al. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis , 2008, Molecular microbiology.
[53] D. T. Walz,et al. Auranofin. New oral gold compound for treatment of rheumatoid arthritis. , 1976, Annals of the rheumatic diseases.
[54] Anil K. Tyagi,et al. Functional Studies of Multiple Thioredoxins from Mycobacterium tuberculosis , 2008, Journal of bacteriology.
[55] E. Shorr,et al. The Influence of Foodstuffs upon the Respiratory Metabolism and Growth of Human Tubercle Bacilli , 1933, Journal of bacteriology.
[56] T. Muth,et al. Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. , 2014, Journal of Inorganic Biochemistry.
[57] J. Imlay,et al. Why do bacteria use so many enzymes to scavenge hydrogen peroxide? , 2012, Archives of biochemistry and biophysics.